Results 1 to 10 of about 664,100 (294)

Lymphoma immunophenotyping: “borderline” lymphomas [PDF]

open access: yesJournal of Cellular and Molecular Medicine, 2000
AbstractImmunophenotyping of B‐cell lymphoproliferative disorders is indispensable, especially in disorders with CD19(+) CD5(+) B lymphocytes, where we have to make the distinction between low grade neoplasia, such as chronic lymphocytic leukemia with CD23(+) malignant lymphocytes, and aggressive neoplasia such as mantle cell lymphoma with CD23 ...
Nicoleta Olteanu   +7 more
openaire   +3 more sources

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas [PDF]

open access: yesZhongguo aizheng zazhi, 2023
CD30 can be expressed in a variety of lymphoma subtypes, among which classical Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL) are the most common ones.
CD-Positive Lymphoma Pathology Expert Group
doaj   +1 more source

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

open access: yesBMC Cancer, 2023
Background Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended.
David K. Lau   +16 more
doaj   +1 more source

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

open access: yesBlood Cancer Journal, 2022
Between 1998 and 2009, a total of 295 patients (median age 58, 53% females) with newly diagnosed early-stage follicular lymphoma (FL) were managed at Memorial Sloan Kettering Cancer Center.
Fushen Sha   +26 more
doaj   +1 more source

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

open access: yesBlood Cancer Journal, 2021
Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear.
Sabela Bobillo   +21 more
doaj   +1 more source

First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature [PDF]

open access: yesТерапевтический архив, 2018
Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen.
N G CHERNOVA   +10 more
doaj   +1 more source

Vitreoretinal Lymphoma [PDF]

open access: yesCancers, 2021
Vitreoretinal lymphoma (VRL) is a rare variant of primary central nervous system lymphoma (PCNSL), mostly of diffuse large B cell lymphoma, which affects the retina and/or the vitreous with or without optic nerve involvement. The disease course is aggressive. Up to 90% of the patients develop central nervous system lymphoma within one year.
Bianka Sobolewska   +7 more
openaire   +2 more sources

How we treat mature B-cell neoplasms (indolent B-cell lymphomas)

open access: yesJournal of Hematology & Oncology, 2021
Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can
Melissa Lumish   +5 more
doaj   +1 more source

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma

open access: yesExperimental Hematology & Oncology, 2023
Background Cell cycle dysregulation characterized by cyclin D1 overexpression is common in mantle cell lymphoma (MCL), while mitotic disorder was less studied. Cell division cycle 20 homologue (CDC20), an essential mitotic regulator, was highly expressed
Yingtong Chen   +9 more
doaj   +1 more source

Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes

open access: yesHaematologica, 2023
Osseous involvement by diffuse large B-cell lymphoma (DLBCL-bone) is a heterogeneous disease. There is limited data regarding response assessment by positron emission tomography with fluorodeoxyglucose, which may demonstrate residual avidity despite a ...
Paola Ghione   +22 more
doaj   +1 more source

Home - About - Disclaimer - Privacy